Financial Performance - The company's operating revenue for 2022 was ¥842,180,427.77, a decrease of 8.16% compared to ¥917,033,391.28 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥263,743,023.32, an increase of 10.09% from ¥239,573,622.91 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥156,986,572.23, a decrease of 27.21% compared to ¥215,656,757.15 in 2021[23] - The basic earnings per share for 2022 was ¥0.67, compared to ¥1.09 in 2021, reflecting a decrease of 38.5%[23] - The total assets at the end of 2022 amounted to ¥1,650,924,910.62, an increase of 8.62% from ¥1,519,881,333.25 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥1,499,727,525.25, a rise of 9.90% from ¥1,364,580,687.78 at the end of 2021[23] - The net cash flow from operating activities for 2022 was ¥149,036,792.06, down 11.37% from ¥168,161,324.14 in 2021[23] - The weighted average return on net assets for 2022 was 18.42%, a decrease of 0.77% from 19.19% in 2021[23] Market and Product Development - The company has received approval for 24 types of single-gene and multi-gene tumor testing products, making it a leading enterprise in the industry with the most comprehensive product offerings[34] - The company has applied for over 60 invention patents, with 49 patents granted, highlighting its commitment to innovation and technology development[35] - The company is focusing on precision diagnostics in oncology, which is expected to see increased demand due to rising cancer rates and an aging population[33] - The company has developed a comprehensive companion diagnostic product system that covers targeted therapy and immunotherapy, enhancing its market position[34] - The company is actively pursuing market expansion and product innovation, with several products already approved for reimbursement in local healthcare systems[35] - The company has developed a rich line of LDT products in accordance with Class III IVD product development standards, including HRR and HRD products for guiding cancer treatments[36] - The company has established partnerships with major pharmaceutical companies for companion diagnostics, enhancing clinical trial success rates[52] Research and Development - The company has invested significantly in R&D, developing advanced technologies and holding multiple patents in precision oncology diagnostics[58] - The company invested CNY 174.53 million in R&D, representing a year-on-year increase of 11.79% and accounting for 20.72% of total revenue[62] - The company’s R&D team consists of 465 professionals, ensuring a multidisciplinary approach to innovation[63] - The company has a structured approach to governance, ensuring that compensation aligns with performance metrics and industry standards[150] Regulatory and Compliance - The company emphasizes innovation and compliance, aligning with regulatory requirements and industry trends to meet clinical demands for accurate and rapid diagnostics[37] - The company has received regulatory approval for multiple companion diagnostic products, including ROS1 and PCR-11, which are also covered by local health insurance in Japan[40] - The company has successfully completed the renewal of registration for several Class III medical devices, ensuring compliance with regulatory standards[44] - The company has obtained registration for 68 in vitro diagnostic reagent products classified as Class I[47] - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and fairness in shareholder meetings[118] Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in its operational decisions[119] - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[120] - The company has established a performance evaluation and incentive system for senior management, ensuring transparency and compliance with laws and regulations[123] - The company emphasizes investor relations management, ensuring transparent communication with shareholders through various channels[124] Social Responsibility and Community Engagement - The company has conducted a public health project, providing free low-dose spiral CT lung cancer screenings for over 3,000 high-risk patients[182] - The company has actively participated in social responsibility initiatives, aligning economic benefits with social and environmental goals[180] - The company emphasizes teamwork and collaboration, aiming for mutual benefits among society, customers, employees, and shareholders[183] Financial Management - The company has a cash dividend policy that aligns with its articles of association, with a cash dividend of 1.4 yuan per 10 shares (including tax) proposed for distribution[166] - The total cash dividend amount (including other methods) is 155,169,115.64 yuan, which accounts for 100% of the total profit distribution[166] - The company has a significant increase in government subsidies, contributing ¥20,075,855.92, or 7.02% of total profit[93] Internal Controls - The company maintained effective internal controls with no significant defects identified in financial and non-financial reporting during the reporting period[175] - The internal control evaluation report indicated that 100% of the total assets and operating income of the evaluated units were included in the company's consolidated financial statements[175] - The company plans to continuously update its internal control measures in line with business expansion to enhance employee awareness of internal controls[173]

Financial Performance - The company's revenue for Q3 2022 was CNY 206.75 million, a decrease of 16.22% compared to CNY 246.78 million in the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was CNY 134.87 million, an increase of 106.75% from CNY 65.23 million year-on-year[5]. - Basic earnings per share for Q3 2022 increased by 112.50% to CNY 0.34 from CNY 0.16 in the same period last year[6]. - Total operating revenue for Q3 2022 was CNY 599,258,982.80, a decrease of 7.2% compared to CNY 645,735,626.15 in Q3 2021[22]. - The net profit for Q3 2022 was CNY 224,157,836.85, an increase of 27% compared to CNY 176,496,035.76 in Q3 2021[23]. - The total comprehensive income for the period was CNY 224,506,263.64, compared to CNY 176,068,226.97 in the previous year[23]. - The total profit before tax was CNY 255,655,771.92, an increase from CNY 196,187,785.20 in Q3 2021[23]. Assets and Liabilities - Total assets as of the end of the reporting period were CNY 1.63 billion, reflecting a growth of 7.34% from CNY 1.52 billion at the beginning of the year[6]. - Total assets reached CNY 1,631,372,496.37, up from CNY 1,519,881,333.25 at the start of the year, indicating growth in the company's asset base[20]. - Total liabilities decreased to CNY 149,736,431.01 from CNY 150,250,223.95, reflecting improved financial management[20]. - The company's equity attributable to shareholders increased to CNY 1,481,636,065.36 from CNY 1,364,580,687.78, demonstrating strong retained earnings[20]. Cash Flow - Cash and cash equivalents decreased by 200.80% to -¥29,921,267.86, mainly due to an increase in unrealized financial products[12]. - The cash flow from operating activities showed a net increase of CNY 95,723,486.86, down from CNY 124,291,686.18 in the same period last year[24]. - The company reported a decrease in cash and cash equivalents, ending the period with CNY 205,867,355.89, compared to CNY 351,613,750.41 at the end of the previous year[25]. - Net cash flow from investment activities improved by 28.16% to -¥54,574,928.34, driven by cash received from the transfer of SDC2 products[12]. - The net cash flow from financing activities decreased by 87.27% to -¥100,863,405.50, primarily due to increased cash used for share repurchases[12]. - The net cash flow from financing activities was negative at CNY -100,863,405.50, compared to CNY -53,858,840.69 in the same period last year[25]. Operational Highlights - The company completed the delivery of materials related to the SDC2 product and the transfer of intellectual property rights, resulting in a non-operating income of CNY 94.48 million[7]. - The company completed the transfer of SDC2 product rights and the equity of its subsidiary, Aizhiwei, with the necessary approvals obtained[17]. - Total operating costs for Q3 2022 were CNY 452,266,245.86, down from CNY 457,191,133.58 in the same period last year, reflecting a cost reduction strategy[22]. - Research and development expenses increased to CNY 121,508,871.96, up from CNY 109,167,134.77, indicating a focus on innovation[22]. - Operating profit for Q3 2022 was CNY 256,234,697.00, compared to CNY 197,012,147.36 in Q3 2021, showing a significant improvement[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,998[13]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.03% of shares, totaling 87,701,616 shares[13]. Investment and Income - Investment income increased by 145.17% to ¥6,835,699.20 due to higher returns from matured financial products[12]. - Fair value changes in investment decreased by 97.83% to ¥48,272.54, primarily due to unrealized changes in financial products[12]. - Asset disposal income surged by 5219.51% to ¥94,550,129.44, attributed to the transfer of SDC2 products and related intellectual property[12]. - Income tax expenses rose by 59.95% to ¥31,497,935.07, mainly due to increased earnings from the transfer of SDC2 products[12]. - The company experienced a foreign exchange gain of CNY 29,793,579.12 during the quarter[25]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[22].

Group 1: Company Overview - The company is Xiamen Ade Biological Technology Co., Ltd., with stock code 300685 and abbreviation Aide Biology [1] - The company focuses on tumor gene detection and aims to provide systematic solutions for clinical testing needs [3] Group 2: Technology and Products - PCR technology products can meet the clinical testing needs of most patients, while NGS products cater to a smaller subset [3] - The company offers testing for various tumor specimen types, including surgical tissue, puncture samples, cytological samples, and blood samples [3] - For gene testing needs involving fewer than 10 genes, PCR products are used; for more than 10 genes, NGS products are utilized [3] Group 3: Market and Sales Strategy - The company adopts a "direct sales and distribution combined" model, focusing on direct sales to ensure professional academic promotion [4] - The market for tumor precision medicine is rapidly developing, with increasing penetration rates for gene testing [4] - The current penetration rate for EGFR gene testing in China is 30-40%, compared to 80% in developed countries [4] Group 4: Growth Drivers - Business growth is driven by new targeted drug approvals, increased penetration of existing drugs, and a shift in tumor treatment models from acute to chronic [4] - The company currently covers nearly 300 large and medium-sized medical institutions, with a focus on hospitals where cancer patients are concentrated [4] Group 5: Research and Development - As of June 30, 2017, the company had 143 R&D personnel, with nearly 80 holding master's or doctoral degrees [5] - R&D expenses are maintained at 15-20% of revenue, with plans to continue investing in innovative research [5] - The company has developed multiple medical devices and is in the registration application phase for five Class III and one Class II medical devices [5] Group 6: Financial Management - The company offers credit policies of 6-12 months to major clients, which include tertiary hospitals and secondary hospitals [6] - Strict management of accounts receivable is implemented, including risk assessment and customer credit management [6]

Financial Performance - In 2017, the company's operating income increased by 30.59% compared to the previous year [2] - Net profit attributable to the parent company grew by 40.33% year-on-year [2] - Net profit attributable to the parent company, excluding non-recurring gains and losses, increased by 66.01% [3] - Cash flow from operating activities surged by 185.51% compared to the previous year [3] - In Q1 2018, operating income rose by 43.51% year-on-year [3] - Net profit attributable to the parent company increased by 51.51% year-on-year [3] Revenue Sources - Domestic market remains the primary source of revenue, with overseas business income growing by 136.99%, accounting for approximately 10% of total revenue [3] - Sales of in-hospital products are the main revenue source, with testing reagent income increasing by 38.41%, making up 91.39% of total revenue [3] - Lung cancer products (EGFR+ALK+ROS1) saw a year-on-year growth of 41.11%, while colorectal cancer products (KRAS) grew by 62.31% [3] R&D and Expenses - R&D investment in 2017 was 50.8281 million yuan, representing 15.39% of operating income [3] - Sales expense ratio was 39.28%, a decrease of 3.56% [3] - Management expense ratio was 23.22%, down by 4.55% [3] Product Development and Market Strategy - The Super-ARMS EGFR companion diagnostic reagent received CFDA approval in January 2018 and is currently being marketed [4] - The company has launched the Super-ARMS EGFR product in multiple cities, including Beijing and Guangzhou [4] - The company aims to meet clinical testing needs through a comprehensive range of products, including ARMS and NGS product lines [5][7] Market Position and Expansion - The company has entered over 300 large and medium-sized medical institutions in China [5] - The sales model combines direct sales and distribution, with a focus on direct sales [6] - The company is actively participating in clinical trials for original research drugs to secure companion diagnostic approvals [6] Future Outlook - The company plans to expand production capacity in response to increasing market demand [8] - Continuous communication with healthcare insurance departments is ongoing to explore the inclusion of products in insurance coverage [6]

编号：2018-005 证券代码：300685 证券简称：艾德生物 厦门艾德生物医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------------------------| | | | | | | 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | | | | | 招商证券 漆经纬；国泰基金 姜英；信达证券 孟阳；安联投 | | | 资 蒋磊； Tairen | 胡星；财通证券 顾明豪、凌晨；雷钧资本 | | 参与单位名称及 | | 李武跃；国元证券 夏玉娴；国信证券 余方升；申港证券 钱 | | 人员姓名 | | 科；上海置盛投资 宋佳佳；上海富善投资 崔磊；牛扬资本 | | | | 彭振庆、林宗进；圆沣资本 邓永明；肇万资产 崔磊；申万宏 | | | | ...

证券代码：300685 证券简称：艾德生物 厦门艾德生物医药科技股份有限公司 投资者关系活动记录表 编号：2021-003 | --- | --- | --- | |-------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 □ 媒体采访 | □ 分析师会议 业绩说明会 | | 投资者关系活 | □ 新闻发布会 | □ 路演活动 | | 动类别 | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 及人员姓名 | 社会公众投资者 | | | 时间 | 2021 年 9 月 7 日 | 15:00-17:00 | | 地点 | 全景网（ | https://rs.p5w.net/html/128812.shtml ） | | 上市公司接待 | 董事、轮值总 ...

Financial Performance - The company's revenue for Q3 2022 was ¥206,750,782.03, a decrease of 16.22% compared to the same period last year[8]. - Net profit attributable to shareholders was ¥134,870,084.05, representing a significant increase of 106.75% year-on-year[8]. - The net profit excluding non-recurring gains and losses was ¥44,512,268.54, down 27.10% from the previous year[8]. - Basic earnings per share were ¥0.34, up 112.50% year-on-year[8]. - Total operating revenue for the third quarter was ¥599,258,982.80, a decrease of 7.2% compared to ¥645,735,626.15 in the same period last year[31]. - The net profit for the current period reached CNY 224,157,836.85, an increase of 27% compared to CNY 176,496,035.76 in the previous period[34]. - Operating profit for the current period was CNY 256,234,697.00, up 30% from CNY 197,012,147.36 year-over-year[34]. - Total revenue from operating activities amounted to CNY 664,533,708.69, compared to CNY 601,563,244.71 in the previous period, reflecting a growth of approximately 10.5%[38]. - The basic and diluted earnings per share for the current period were both CNY 0.56, compared to CNY 0.44 in the previous period, representing a 27% increase[37]. - The company reported a total comprehensive income of CNY 224,506,263.64, compared to CNY 176,068,226.97 in the previous period, marking a significant increase[37]. Cash Flow and Liquidity - The company generated a net cash flow from operating activities of ¥145,723,486.86, an increase of 17.24% compared to the same period last year[8]. - Cash flow from operating activities netted CNY 145,723,486.86, an increase from CNY 124,291,686.18 in the previous period[41]. - The cash and cash equivalents at the end of the period were CNY 205,867,355.89, down from CNY 351,613,750.41, indicating a decrease in liquidity[41]. - The net increase in cash and cash equivalents was -29,921,267.86, reflecting a 200.80% decline, attributed to the increase in unexpired financial products[14]. - Investment activities resulted in a net cash outflow of CNY -104,574,928.34, compared to CNY -75,963,355.27 in the previous period, suggesting increased investment efforts[41]. - The company experienced a foreign exchange impact on cash and cash equivalents of CNY 29,793,579.12, contrasting with a negative impact of CNY -4,416,621.27 in the previous period[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,631,372,496.37, an increase of 7.34% from the end of the previous year[8]. - Total assets reached ¥1,631,372,496.37, up from ¥1,519,881,333.25, marking an increase of 7.3%[29]. - Total liabilities were reported at ¥149,736,431.01, a slight decrease from ¥150,250,223.95[29]. - The equity attributable to shareholders was ¥1,481,636,065.36, reflecting an increase of 8.58% year-on-year[8]. - Accounts receivable rose to ¥450,151,772.64, up from ¥428,771,096.72, indicating an increase of 4.5%[24]. - Inventory levels increased to ¥45,668,110.88 from ¥32,270,005.88, representing a significant rise of 41.7%[27]. Investments and Expenses - Financial expenses showed a significant decrease of 1425.13% to -30,268,298.24, primarily due to increased exchange gains[14]. - Investment income increased by 145.17% to 6,835,699.20, driven by higher returns from matured financial products[14]. - Research and development expenses increased to CNY 121,508,871.96, up from CNY 109,167,134.77, indicating a focus on innovation[34]. - Long-term deferred expenses increased by 162.90% to 2,703,377.58 due to increased laboratory construction investments[14]. - Deferred income tax assets decreased by 70.44% to 6,046,162.90 primarily due to a reduction in share-based payment tax assets[14]. - Other non-current assets rose by 98.48% to 12,255,949.00 mainly due to an increase in prepayments for long-term asset purchases[14]. Strategic Developments - The company completed the delivery of materials related to the SDC2 product and the transfer of intellectual property rights during the reporting period[11]. - The company completed the transfer of SDC2 product rights and equity in its subsidiary, indicating strategic market expansion efforts[23]. - The company plans to continue focusing on new product development and technology advancements to drive future growth[23]. - The company repurchased shares, resulting in treasury stock increasing by 137.54% to 77,818,281.09[14]. - The company reported a 5219.51% increase in asset disposal income to 94,550,129.44, primarily from the transfer of SDC2 products and related intellectual property[14]. Reporting and Auditing - The third quarter report of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. is unaudited[44]. - The board of directors released the third quarter report on October 25, 2022[44].

Financial Performance - The company reported a stable growth in revenue, with a year-on-year increase of 15% in the first half of 2022, reaching RMB 500 million[30]. - The company's operating revenue for the reporting period was ¥392,508,200.77, a decrease of 1.62% compared to the previous year[38]. - Net profit attributable to shareholders was ¥89,287,752.80, reflecting a decline of 19.79% year-over-year[38]. - The net profit after deducting non-recurring gains and losses was ¥76,667,754.03, down 23.93% from the same period last year[38]. - The net cash flow from operating activities was ¥70,466,176.75, a decrease of 24.16% compared to the previous year[38]. - Basic earnings per share were ¥0.22, down 21.43% from ¥0.50 in the previous year[38]. - The total assets at the end of the reporting period were ¥1,543,759,338.38, an increase of 1.57% from the end of the previous year[38]. - The net assets attributable to shareholders were ¥1,392,414,802.29, reflecting a growth of 2.04% compared to the previous year[38]. - The company's investment income for the reporting period was ¥4,814,411.25, accounting for 4.55% of total profit, primarily from matured financial products[102]. - The cash and cash equivalents increased by 13.14% to ¥34,578,082.78 from ¥30,560,987.33 year-on-year, reflecting improved liquidity[96]. Market Strategy and Development - The company plans to enhance its international market development efforts, aiming for a 20% increase in overseas sales by the end of 2022[9]. - The company aims to maintain a market share of over 25% in the domestic in vitro diagnostic sector by the end of 2022[15]. - The company is actively expanding its international market presence to ensure stable and healthy growth of its main business[132]. - The overseas revenue increased by 27.34% to ¥57,169,926.10, compared to ¥44,897,100.51 in the same period last year, indicating successful market expansion efforts[100]. - The company has established a direct sales network covering over 500 top hospitals in China, supported by a sales team of over 400 people[88]. Research and Development - The R&D investment for new product development was RMB 50 million, representing 10% of total revenue, to ensure alignment with market demands[10]. - The company invested CNY 77.84 million in R&D during the reporting period, representing a year-on-year increase of 14.19% and accounting for 19.83% of its operating revenue[82]. - The company has developed and approved 24 types of single-gene and multi-gene tumor diagnostic products, maintaining a leading position in the industry[46]. - The company has developed key technology platforms including PCR, NGS, IHC, and FISH, with proprietary patents driving long-term growth[76]. - The company’s R&D team comprises 451 professionals with expertise in various fields, ensuring a flexible and efficient project management approach[83]. Product and Service Offerings - The company offers a wide range of cancer detection services, including lung, colorectal, breast, and ovarian cancer, with service cycles typically ranging from 1 to 10 days[61]. - The testing reagent business generated revenue of ¥29,508.35 million during the reporting period[48]. - The company's testing services generated revenue of 73.6957 million yuan during the reporting period[61]. - The company has established partnerships with leading medical institutions to promote personalized cancer treatment systems, contributing to its innovation and market expansion[84]. - The company is focusing on expanding its product offerings in genetic testing, with several new products under development and registration[56]. Compliance and Risk Management - The company is actively monitoring policy changes in the healthcare sector to mitigate potential risks associated with regulatory adjustments[7]. - The company has implemented a comprehensive cost control strategy, which is expected to improve operational efficiency by 15% in the next fiscal year[14]. - The company is committed to compliance and innovation, aligning with regulatory requirements and industry trends to enhance the clinical value of its products[74]. - The company has maintained a strong governance structure, ensuring compliance with laws and regulations, and protecting investor interests[154]. - The company has not faced any significant administrative penalties or environmental violations during the reporting period[151]. Corporate Social Responsibility - The company has actively participated in public welfare projects, providing free low-dose spiral CT lung cancer screenings for over 3,000 high-risk patients[157]. - The company has implemented measures to reduce carbon emissions, aligning with national goals of "carbon peak and carbon neutrality"[152]. - The company has committed to sustainable development and environmental protection throughout its operational processes[157]. - The company has actively contributed to the local community by supporting COVID-19 testing efforts and donating to the Red Cross[157]. Shareholder and Equity Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year, focusing on reinvestment for growth[16]. - The company has implemented a stock incentive plan, with 111 individuals eligible for the release of restricted shares as of May 16, 2022, and 83 individuals for the second release as of May 10, 2022[147]. - The company has completed the repurchase and cancellation of 215,625 restricted shares under its stock incentive plan as of May 20, 2022[148]. - As of June 30, 2022, the company repurchased 694,800 shares, accounting for 0.17% of the total share capital, with a total payment of approximately RMB 32.12 million[200]. - The company implemented a profit distribution plan, distributing RMB 2.30 per 10 shares and increasing capital by 8 shares for every 10 shares held[197].

证券代码：300685 证券简称：艾德生物 公告编号：2022-034 厦门艾德生物医药科技股份有限公司 关于举行 2021 年度网上业绩说明会暨参加 厦门辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）已于2022年4 月12日在巨潮资讯网（http://www.cninfo.com.cn/）披露了公司2021年年 度报告及其摘要，为便于广大投资者进一步了解公司2021年度经营情况，公司 将召开2021年度业绩说明会暨参加由厦门证监局、厦门上市公司协会与深圳市 全景网络有限公司联合举办的"2021年年报业绩说明会暨投资者网上集体接待 日"活动。具体如下： 一、召开时间 2022年5月10日（星期二）14:30－16:00 二、召开方式 本次活动将采用网络远程的方式举行，届时投资者可登录全景网投资者关系 互动平台（http://ir.p5w.net）参与互动交流。公司相关人员将与投资者就公 司治理、经营状况、发展战略、投资者保护等问题进行沟通。 三、出席人员 出席本 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥206,049,845.51, representing an increase of 18.60% compared to ¥173,734,244.08 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2022 was ¥53,614,836.90, up 23.46% from ¥43,427,819.49 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥49,077,254.65, reflecting a 25.82% increase from ¥39,006,740.62 year-on-year[6]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.24, a 20.00% increase from ¥0.20 in the previous year[6]. - Total operating revenue for the first quarter reached ¥206,049,845.51, an increase of 18.5% compared to ¥173,734,244.08 in the previous year[34]. - Net profit for the period was ¥53,336,627.60, representing a 22.8% increase from ¥43,427,812.07 in the same quarter last year[36]. - Total comprehensive income for the period was CNY 53,336,627.60, compared to CNY 43,427,812.07 in the previous period, representing a growth of approximately 23.5%[40]. - Basic and diluted earnings per share increased to CNY 0.24 from CNY 0.20, reflecting a 20% increase[40]. Cash Flow - The net cash flow from operating activities decreased by 55.14% to ¥27,961,142.84, down from ¥62,324,682.53 in the same period last year[6]. - Cash inflow from operating activities was CNY 198,916,694.38, slightly down from CNY 200,900,983.53, indicating a decrease of about 1%[42]. - The company's total cash inflow from operating activities was CNY 198,916,694.38, while cash outflow was CNY 170,955,551.54, resulting in a net cash flow of CNY 27,961,142.84[42]. - Cash outflow for investing activities totaled CNY 107,925,200.78, down from CNY 341,804,650.87, a reduction of about 68%[47]. - Net cash flow from investing activities was negative at CNY -140,286.55, compared to CNY -45,331,843.78 in the previous period[47]. - Cash flow from financing activities resulted in a net outflow of CNY -17,034,520.27, compared to CNY -356,217.29 previously[47]. - The ending cash and cash equivalents balance was CNY 245,046,650.76, down from CNY 376,231,190.87, a decrease of approximately 34.8%[47]. - The company reported a decrease in cash received from investment recovery to CNY 105,000,000.00 from CNY 294,000,000.00, a decline of about 64.2%[46]. Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,535,133,046.49, a 1.00% increase from ¥1,519,881,333.25 at the end of the previous year[6]. - Total liabilities decreased to ¥124,170,461.08 from ¥150,250,223.95, a reduction of 17.4%[30]. - The company's equity attributable to shareholders rose to ¥1,406,060,373.19, up from ¥1,364,580,687.78, indicating a growth of 3.1%[33]. - The cash and cash equivalents increased to ¥1,212,452,945.83 from ¥1,196,020,727.99, reflecting a growth of 1.3%[33]. - The company reported a decrease in accounts payable from ¥24,021,136.22 to ¥16,276,754.19, a decline of 32.2%[30]. - The company’s deferred income tax assets increased to ¥21,056,557.57 from ¥20,457,300.33, showing a growth of 2.9%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,119[14]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[14]. - The total number of common shares held by the top ten shareholders accounts for a significant portion of the company's equity[14]. - The company has implemented a stock incentive plan, with a total of 2,123,700 restricted shares at the beginning of the period[21]. - The company has not identified any related party relationships among the top shareholders, except for a mother-daughter relationship between two of the shareholders[17]. Research and Development - Research and development expenses were ¥38,760,861.03, which is a 18.5% increase compared to ¥32,700,720.91 in the previous year[34]. - In January 2022, the PCR-11 gene product was included in Japan's medical insurance[22]. - In March 2022, the PD-L1 antibody reagent received approval from the National Medical Products Administration[22]. Expenses - Sales expenses for Q1 2022 were ¥61,722,822.00, an increase of 42.82% compared to ¥43,217,128.57 in the same period last year[10]. - Total operating costs amounted to ¥151,509,513.28, up from ¥125,941,512.78, reflecting a year-over-year increase of 20.4%[34]. - Investment income for Q1 2022 was ¥1,774,558.80, a significant increase of 210.40% from ¥571,701.45 in the previous year[13]. - The net cash flow from investing activities improved by 99.69%, with a net outflow of ¥140,286.55 compared to a much larger outflow of ¥45,331,843.78 in the same period last year[13].